What the Evidence Says About Medicinal Cannabis in Australia | Research

The takeaway

A review of therapeutic cannabis evidence found limited but possible clinical uses for multiple sclerosis spasticity, cancer-related nausea, cancer pain, and HIV neuropathy, while emphasizing the need for regulatory safeguards.

Read this if you are interested in the evidence basis for medicinal cannabis or Australian drug policy.

Evidence described as limited and not conclusive for any indication

What the researchers found

This review examined the clinical evidence for medicinal cannabis and its derivatives in Australia's regulatory context. Possible clinical indications included spasticity and pain in multiple sclerosis, chemotherapy-induced nausea, cancer pain, and HIV neuropathy.

However, the review emphasized that evidence was limited, often reflected subjective rather than objective outcomes, and was not conclusive for any indication. At the time, nabiximols (Sativex) was the only cannabinoid on Australia's therapeutic goods register, and cannabidiol was being considered for scheduling.

The review stressed that introducing cannabinoids therapeutically should be supported by regulatory and educational frameworks that minimize risks to patients and the community.

Why it matters

This review captured a pivotal moment in Australian medical cannabis policy, when legislative frameworks were being developed. It provided clinicians with a balanced evidence summary while acknowledging the gap between public enthusiasm and clinical proof.

The numbers in context

One cannabinoid product on Australian register (nabiximols); CBD recommended for Schedule 4; Regulator of Medicinal Cannabis Bill 2014 under consideration

How the study worked

Narrative review published in Australian Prescriber, examining clinical evidence for medicinal cannabis and the regulatory landscape in Australia as of 2015.

What this study cannot tell us

Brief overview rather than systematic review. Focused on the Australian regulatory context. Evidence quality for most indications was described as limited and not conclusive.

How to read the evidence

Brief narrative review summarizing available evidence for an Australian clinical audience. Useful for policy context but not a comprehensive evidence synthesis.

When this study was published

Published in 2015. Australia has since implemented a medicinal cannabis access scheme, and additional evidence has accumulated.

The bigger picture

Australia went on to establish a medicinal cannabis access scheme. This review represents the evidence base that informed early policy decisions, highlighting how limited the data was even as the policy moved forward.

Questions still open

Has the evidence base for medicinal cannabis strengthened since 2015? What has Australia's experience been with regulated medicinal access? Are patient-reported subjective benefits sufficient to justify therapeutic use?

Common questions

Is medicinal cannabis proven to work?

As of this 2015 review, evidence was described as limited and not conclusive for any specific indication. The strongest, though still limited, support was for MS spasticity, chemotherapy nausea, cancer pain, and HIV neuropathy.

What is nabiximols?

Nabiximols (brand name Sativex) is a mouth spray containing THC and CBD. It was the only cannabinoid on Australia's therapeutic register at the time, used primarily for MS spasticity and pain.

Read the original research

Medicinal cannabis.

Australian prescriber, 38(6), 212-5

View on PubMed ↗

Citation

Murnion, Bridin. (2015). Medicinal cannabis.. Australian prescriber, 38(6), 212-5.